Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.

<h4>Background</h4>HIV viral load (VL) is currently not part of the criteria for Pneumocystis jirovecii pneumonia (PCP) prophylaxis discontinuation, but suppression of plasma viremia with antiretroviral therapy may allow for discontinuation of PCP prophylaxis even with CD4 count <200...

Full description

Saved in:
Bibliographic Details
Main Authors: Cecilia T Costiniuk, Dean A Fergusson, Steve Doucette, Jonathan B Angel
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0028570&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850110229713256448
author Cecilia T Costiniuk
Dean A Fergusson
Steve Doucette
Jonathan B Angel
author_facet Cecilia T Costiniuk
Dean A Fergusson
Steve Doucette
Jonathan B Angel
author_sort Cecilia T Costiniuk
collection DOAJ
description <h4>Background</h4>HIV viral load (VL) is currently not part of the criteria for Pneumocystis jirovecii pneumonia (PCP) prophylaxis discontinuation, but suppression of plasma viremia with antiretroviral therapy may allow for discontinuation of PCP prophylaxis even with CD4 count <200 cells/µL.<h4>Methods</h4>A systematic review was performed to determine the incidence of PCP in HIV-infected individuals with CD4 count <200 cells/µL and fully suppressed VL on antiretroviral therapy but not receiving PCP prophylaxis.<h4>Results</h4>Four articles examined individuals who discontinued PCP prophylaxis with CD4 count <200 cells/µL in the context of fully suppressed VL on antiretroviral therapy. The overall incidence of PCP was 0.48 cases per 100 person-years (PY) (95% confidence interval (CI) (0.06-0.89). This was lower than the incidence of PCP in untreated HIV infection (5.30 cases/100 PY, 95% CI 4.1-6.8) and lower than the incidence in persons with CD4 count <200 cells/µL, before the availability of highly active antiretroviral therapy (HAART), who continued prophylaxis (4.85/100 PY, 95% CI 0.92-8.78). In one study in which individuals were stratified according to CD4 count <200 cells/µL, there was a greater risk of PCP with CD4 count ≤100 cells/µL compared to 101-200 cells/µL.<h4>Conclusion</h4>Primary PCP prophylaxis may be safely discontinued in HIV-infected individuals with CD4 count between 101-200 cells/µL provided the VL is fully suppressed on antiretroviral therapy. However, there are inadequate data available to make this recommendation when the CD4 count is ≤100 cells/µL. A revision of guidelines on primary PCP prophylaxis to include consideration of the VL is merited.
format Article
id doaj-art-021f1ae327ae4879ae3053e542ea241c
institution OA Journals
issn 1932-6203
language English
publishDate 2011-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-021f1ae327ae4879ae3053e542ea241c2025-08-20T02:37:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01612e2857010.1371/journal.pone.0028570Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count &lt;200 cells/µL and virologic suppression: a systematic review.Cecilia T CostiniukDean A FergussonSteve DoucetteJonathan B Angel<h4>Background</h4>HIV viral load (VL) is currently not part of the criteria for Pneumocystis jirovecii pneumonia (PCP) prophylaxis discontinuation, but suppression of plasma viremia with antiretroviral therapy may allow for discontinuation of PCP prophylaxis even with CD4 count <200 cells/µL.<h4>Methods</h4>A systematic review was performed to determine the incidence of PCP in HIV-infected individuals with CD4 count <200 cells/µL and fully suppressed VL on antiretroviral therapy but not receiving PCP prophylaxis.<h4>Results</h4>Four articles examined individuals who discontinued PCP prophylaxis with CD4 count <200 cells/µL in the context of fully suppressed VL on antiretroviral therapy. The overall incidence of PCP was 0.48 cases per 100 person-years (PY) (95% confidence interval (CI) (0.06-0.89). This was lower than the incidence of PCP in untreated HIV infection (5.30 cases/100 PY, 95% CI 4.1-6.8) and lower than the incidence in persons with CD4 count <200 cells/µL, before the availability of highly active antiretroviral therapy (HAART), who continued prophylaxis (4.85/100 PY, 95% CI 0.92-8.78). In one study in which individuals were stratified according to CD4 count <200 cells/µL, there was a greater risk of PCP with CD4 count ≤100 cells/µL compared to 101-200 cells/µL.<h4>Conclusion</h4>Primary PCP prophylaxis may be safely discontinued in HIV-infected individuals with CD4 count between 101-200 cells/µL provided the VL is fully suppressed on antiretroviral therapy. However, there are inadequate data available to make this recommendation when the CD4 count is ≤100 cells/µL. A revision of guidelines on primary PCP prophylaxis to include consideration of the VL is merited.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0028570&type=printable
spellingShingle Cecilia T Costiniuk
Dean A Fergusson
Steve Doucette
Jonathan B Angel
Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count &lt;200 cells/µL and virologic suppression: a systematic review.
PLoS ONE
title Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count &lt;200 cells/µL and virologic suppression: a systematic review.
title_full Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count &lt;200 cells/µL and virologic suppression: a systematic review.
title_fullStr Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count &lt;200 cells/µL and virologic suppression: a systematic review.
title_full_unstemmed Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count &lt;200 cells/µL and virologic suppression: a systematic review.
title_short Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count &lt;200 cells/µL and virologic suppression: a systematic review.
title_sort discontinuation of pneumocystis jirovecii pneumonia prophylaxis with cd4 count lt 200 cells µl and virologic suppression a systematic review
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0028570&type=printable
work_keys_str_mv AT ceciliatcostiniuk discontinuationofpneumocystisjiroveciipneumoniaprophylaxiswithcd4countlt200cellsμlandvirologicsuppressionasystematicreview
AT deanafergusson discontinuationofpneumocystisjiroveciipneumoniaprophylaxiswithcd4countlt200cellsμlandvirologicsuppressionasystematicreview
AT stevedoucette discontinuationofpneumocystisjiroveciipneumoniaprophylaxiswithcd4countlt200cellsμlandvirologicsuppressionasystematicreview
AT jonathanbangel discontinuationofpneumocystisjiroveciipneumoniaprophylaxiswithcd4countlt200cellsμlandvirologicsuppressionasystematicreview